SCHEMBL7547291

SCHEMBL7547291

COc1cccc(C(CC2=NCCN2)c2nccc3ccccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 11/20 0.48
HTR1B P28222 1/20 0.47
MAOA P21397 4/20 0.46
MAOB P27338 4/20 0.46
TAAR1 Q96RJ0 3/20 0.42
MAPK1 P28482 2/20 0.42
LMNA P02545 2/20 0.42
CYP2D6 P10635 2/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
MAPT P10636 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRM1 P35372 1/20 0.42
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549185 0.80 NISCH (0.53) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7553949 0.79 NISCH (0.49) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7550070 0.79 NISCH (0.60) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7547494 0.76 NISCH (0.50) NISCHMAOAMAOBTAAR1MAPK1
SCHEMBL7554011 0.74 NISCH (0.45) NISCHHTR1BMAOAMAOBMTNR1A
SCHEMBL7546294 0.71 NISCH (0.52) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7546324 0.71 NISCH (0.52) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7550483 0.68 NISCH (0.75) NISCHHTR1BMAOAMAOBTAAR1
SCHEMBL7547171 0.68 NISCH (1.00) NISCHMAOAMAOBTAAR1LMNA
SCHEMBL7550085 0.66 NISCH (0.51) NISCHMAOAMAOBTAAR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US claimed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO claimed
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 NISCH 448/4885HTR1B 3118/4885MAOA 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.